162P - Statin use and survival in malignant pleural mesothelioma (MPM)

Date 17 April 2015
Event ELCC 2015
Session Poster lunch
Topics Mesothelioma
Presenter Susana Cedres
Citation Annals of Oncology (2015) 26 (suppl_1): 48-50. 10.1093/annonc/mdv052
Authors S. Cedres, A. Navarro, A. Martinez, P. Martinez, C. Ortiz, L. Fariñas, E. Felip
  • Medical Oncology, Vall d`Hebron University Hospital Institut d'Oncologia, 08035 - Barcelona/ES



Malignant pleural mesothelioma (MPM) is an aggressive tumor linked to asbestos exposure. There is evidence that statins may have antitumor effects in some malignancies but the effects of statins on prognosis of MPM have not yet been examined. We conducted this study evaluating the influence of statins use on survival in patients with MPM.


Fifty five patients (p) diagnosed with MPM in Vall d'Hebron University Hospital between November 2002 and September 2013 were retrospectively reviewed. Baseline factors analyzed were age, gender, performance status (PS), histology, stage, chemotherapy (CT) and use of statins. Survival data were calculated by the Kaplan-Meier method.


Patient's characteristics: median age 68 years (31-88years), males 71.7%, PS 1:59.8%, asbestos exposure 57.6%, chest pain 73.9%, dyspnea 75%, clinical stage III 45% and IV 39%, epithelial subtype 69.6%, statin users 77%. All patients were considered initially unresectable and 79.3% received CT in 1st line and 42.4 % in 2nd. After a median follow up of 13 months the median OS was 13.3 months. We found significant increase in OS in patients with epithelial subtype (19.7 vs 5.0 months in no-epithelial, p < 0.001), patients without chest pain (23.3 v 12.4, p = 0.012), PS1 (13.3 vs 2.5 months in PS 2, p = 0.011) and patients who received 2nd line CT (25.5 vs 9.6 months, p = 0.003). In the analysis of statins, the OS for statins users was 18.1 months and 9.5 months for non- statins users (p = 0.17). No differences were detected in OS for prediagnostic and postdiagnostic users of statins (p > 0.05).


In our study epithelial subtype, chest pain, PS, and treatment with second line therapy are prognostic factors for survival in MPM p. In this study there is some evidence that use of statins may improve OS.


All authors have declared no conflicts of interest.